Roche Holding AG Stock News

Roche Holding AG is the latest drug maker trying to take advantage of the booming demand for weight-loss drugs.

Roche said Carmot Therapeutics' research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche's a

Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.

Roche is expanding its obesity drug pipeline with the acquisition of Carmot Therapeutics for up to US$3.1 billion. Per the agreement, Roche will pay US$2.7 billion upfront to acquire private biotechno

Teresa Graham, CEO of Roche Pharmaceuticals, says its takeover of anti obesity drug developer Carmot Therapeutics will bolster the company's weight-loss treatments, including via potential oral pills.

Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke

Roche Holding AG will pay as much as $3.1 billion for Carmot Therapeutics Inc., in a deal that includes three experimental medicines in obesity and diabetes. Eric Pfanner reports on Bloomberg Televisi

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion, as the world's top drugmakers rush to capitalize on the booming market for weight-loss drugs that has seen No

Pharmaceutical giant Roche said on Monday it has entered into a definitive agreement to acquire Carmot Therapeutics , a US company based in Berkeley.

David Roche of Independent Strategy says it's clear that the U.S. Federal Reserve is done raising interest rates, "which means the next move is down."

After a 14% fall this year, Roche stock (OTCMKTS: RHHBY) looks like it can see higher levels.

Swiss drugs and diagnostics maker Roche is investing $240 million in Colombia over five years as part of its plan to consolidate its presence in the country, a high-ranking executive said on Thursday.

Roche's (RHHBY) subcutaneous (SC) formulation of immuno-oncology drug Tecentriq gets CHMP's positive recommendation for all approved indications.

Roivant Sciences has reported a third-quarter earnings miss but revenue that topped analysts' expectations, sending its shares higher in Monday premarket trading. The company also said it has sufficie